Exosomal PD-L1 predicts response with immunotherapy in NSCLC patients.
|
| Abstract |
Immune Check-Point Inhibitors (ICIs) have shown remarkable promise in treating tumors, including non-small cell lung cancer (NSCLC). Nevertheless, the treatment response rate is low. Studies have found that the high expression of exosomal PD-L1 is one of the reasons for the low treatment response. Therefore, this study focused on the relationship between the exosomal PD-L1 and the clinical response to immunotherapy in NSCLC patients to evaluate whether it could be used as a biomarker to predict the efficacy of ICIs. In this study, clinical information and blood samples of 149 NSCLC patients receiving ICIs were collected. The expression level of exosomal PD-L1 was detected by enzyme-linked immunosorbent assay method, and the relationship between exosomal PD-L1 and the efficacy of ICIs was explored. Overall, our study found that the expression level of exosomal PD-L1 was lower at pre-treatment, or the max fold increasing change higher at 3-6 weeks had a higher disease control rate and longer progression-free survival. It revealed that the exosomal PD-L1 was associated with the treatment response of patients using ICIs and provided a new tool for the evaluation of clinical efficacy of lung cancer immunotherapy.
|
|---|---|
| Authors | Yuting Wang, Xiaomin Niu, Yirui Cheng, Yanshuang Zhang, Liliang Xia, Weiliang Xia, Shun Lu |
| Journal | Clinical and experimental immunology (Clin Exp Immunol) Vol. 208 Issue 3 Pg. 316-322 (06 23 2022) ISSN: 1365-2249 [Electronic] England |
| PMID | 35514075 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't) |
| Copyright | © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Immunology. All rights reserved. For permissions, please e-mail: [email protected]. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!